Valeant Pharmaceuticals calls $445 million 6 7/8% senior notes due 2018

By Susanna Moon

Chicago, Dec. 1 – Valeant Pharmaceuticals International, Inc. said wholly owned subsidiary Valeant Pharmaceuticals International called $445 million principal amount of its outstanding 6 7/8% senior notes due 2018.

After the redemption on Dec. 29, there will be about $500 million principal amount of the notes left outstanding, according to a company press release.

The Bank of New York Mellon Trust Co., NA is the trustee.

Valeant is a Laval, Quebec-based specialty pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.